iQ3Corp Ltd Overview
| Field | Detail | Source |
|---|---|---|
| Legal name | iQ3Corp Ltd (Administrators Appointed) | Federal Court of Australia, [2022] FCA 397 (6 Apr 2022) |
| Former names | None recorded | Market Index IQ3 profile |
| ACN | 160 238 282 | FY2020 Annual Report cover; [2022] FCA 397 |
| Incorporation year | 2,012 | MarketBeat / Investing.com company profiles (aggregator); consistent with ACN series |
| Incorporation jurisdiction | Australia (public company limited by shares, Corporations Act 2001 (Cth)) | FY2020 AR, Note 1 |
| Registered office / HQ (last reported) | Level 9, 85 Castlereagh Street, Sydney NSW 2000 | FY2020 AR, Corporate Directory |
| Share registry | Boardroom Pty Limited, Level 12, 225 George Street, Sydney NSW 2000 | FY2020 AR |
| Exchange / ticker | ASX: IQ3 (listed 18 May 2015; suspended; removed 26 Aug 2022) | [2022] FCA 397; ASX Market Announcement 29 Aug 2022 |
| ISIN | Not publicly disclosed in sources retrieved (AU-prefixed ISIN would have applied) | — |
| CUSIP | Not applicable (no US listing) | — |
| Fiscal year end | 30 June | FY2020 AR |
| Employees | Not publicly disclosed. Proxy: employee benefits expense A$1.76m (FY2020) vs A$2.87m (FY2019) | FY2020 AR, Note 7 |
| Auditor (last) | Vincents Audit Pty Ltd, Canberra (engagement director Phillip William Miller CA) | FY2020 AR, auditor's independence declaration |
| Regulatory licence status | Corporate authorised representative of AFSL 451144 | FY2020 AR, Review of operations |
| Shares on issue (30 Jun 2020) | 103,925,001 fully paid ordinary shares | FY2020 AR, Note 20 |
| Market capitalisation (current) | Not applicable (delisted). Last quoted price A$0.12, implying about A$12.5m on 103.9m shares (historical, illiquid) | Investing.com historical data |
| Market capitalisation at IPO | A$30.545m at A$0.30 per share | IPO close announcement, May 2015 |
| Website | http://iq3corp.com (as supplied; www.iQ3Corp.com cited in FY2020 AR). | FY2020 AR |
| External administrators | Mark Robinson, Riad Tayeh and Antony Resnick (joint and several) | [2022] FCA 397 |
iQ3Corp Ltd was a micro-cap Australian corporate finance boutique that described itself as the world's first dedicated life science corporate finance and advisory firm. It provided capital raising, IPO and listing advisory, M&A, structured finance, restructuring and NSX nominated-adviser services to biotech, medtech and pharmaceutical companies in Australia and, through US subsidiaries, the United States. In practice it was a captive service provider inside the "iQ Group" of companies founded by Dr George Syrmalis. Its FY2020 accounts state that 100% of revenue came from related parties, and the group's administrators later described a web of intercompany loans and shared-labour arrangements. Revenue grew from A$2.1m (FY2016) to A$6.9m (FY2020), but losses widened, equity turned negative and the auditor flagged a going-concern material uncertainty. The group collapsed into voluntary administration in March 2022, and iQ3Corp was delisted from the ASX in August 2022. It is now a distressed-asset and governance case study rather than a going concern.
Company's own description (FY2020 Annual Report)
The FY2020 Directors' Report gives the principal activity as the provision of capital raising and corporate advisory services to listed and unlisted companies in the life science industry. The Review of Operations positions the company as a specialist corporate finance adviser to the life science sector. It describes expertise in mergers and acquisitions, strategic matters, restructuring and capital structure, and capital raising, offered to corporations, partnerships, institutions, governments and individuals. The FY2019 Annual Report called iQ3Corp the world's first dedicated life science corporate finance firm, under the tagline "Translating Science into Capital and Beyond".
In FY2020 management said the company had advised boards and executives on the best business model for commercialising new life science intellectual property. That work covered market entry, funding, licensing and partnering strategies, and identifying counterparties in Australia and offshore. Management also cited new projects and collaborations with US business partners, which it expected to produce a pipeline of work over the following 12–24 months.
Aggregator profiles (MarketBeat, Investing.com) add IPO and listing advisory, private equity, structured finance, sell-side and buy-side mandates, and NSX nominated-adviser services to the list.
Business model and revenue model
| Revenue stream | Model type | FY2020 (AUD) | FY2019 (AUD) | Share of FY2020 revenue |
|---|---|---|---|---|
| Capital raising and corporate advisory fees | Professional services: project/success fees, fixed price or hourly | 6,760,211 | 5,647,659 | 98.0% |
| Office and shared services revenue | Cost-recovery / service fees charged to related entities | 139,757 | 513,190 | 2.0% |
| Total | — | 6,899,968 | 6,160,849 | 100% |
Source: FY2020 Annual Report, Notes 4 and 5. All revenue was recognised over time as services were rendered, on either a fixed price or an hourly rate (Note 5 accounting policy). There was no product, subscription or licensing revenue. The company did hold "licences" as an indefinite-life intangible asset (A$307,986 at 30 June 2020), but these generated no disclosed revenue.
Independent characterisation
On paper, iQ3Corp was an advisory boutique. Economically, it functioned as a related-party service vehicle. Three disclosures from FY2020 are decisive:
-
Customer concentration of 100% to related parties. Note 4 states that the Group's revenue came only from related parties. Note 30 confirms that all A$6.76m of advisory fees and all A$0.14m of shared-services fees were received from related parties. The related entities were The iQ Group Global Ltd (formerly iQnovate), iQX Limited, OncoTEX entities, Biosensx (North America) Pty Ltd and New Frontier Holdings LLC.
-
Cash conversion was weak. Related-party receivables were A$2.48m gross at 30 June 2020, against FY2020 revenue of A$6.90m, or roughly 126 days of revenue.
-
Funding came from inside the group. Liquidity relied on a A$927,000 bond from related party iQX (9% coupon, maturing 30 June 2022) and an undrawn A$3m iQX working capital facility, also at 9%. The going-concern basis rested on related-party capital-raising fees and related-party funding.
The auditor's key audit matters were going concern, related party transactions, and recognition and impairment of intangibles. The audit report described a group of subsidiaries and companies with varying ownership levels, which transacted with one another and performed similar functions in different market sectors.
The administrators' evidence to the Federal Court in April 2022 confirmed this picture. Entities in the iQ Group relied on each other for day-to-day funding. There were many intercompany loans, often written off or reclassified without adequate explanation, and loan balances were inconsistent between counterparties. Entities sometimes paid other entities' employees, and shared-labour arrangements were common. The administrators considered Farmaforce, not iQ3Corp, to be the group's principal operating company ([2022] FCA 397, paras 4–5).
Value chain position
| Value-chain stage | Activity | iQ3Corp role |
|---|---|---|
| Discovery / IP origination | University and research-institute IP, early-stage biotech | None directly; sourced via sister company iQ Group Global (IP asset manager) |
| Corporatisation and structuring | Company formation, IP licensing, structuring | Advisory (stated FY2020 focus: "finding, funding, corporatising and capitalising early stage biotech assets", per Lei Xu biography) |
| Capital raising | Seed, pre-IPO, IPO, secondary raisings | Core fee-earning service |
| Listing / nominated adviser | ASX and NSX listings; NSX nominated adviser | Service offered (NSX nominated adviser per aggregator profiles) |
| Investment / funds management | Bioscience funds | Sister company iQX Limited (NSX: IQX) |
| Commercial execution | Pharma sales forces, medical affairs | Sister company Farmaforce Ltd (ASX: FFC) |
iQ3Corp sat between life science asset originators and capital markets:
Customer types and end-markets
| Customer type | Evidence | Notes |
|---|---|---|
| Related-party life science companies | FY2020 AR Note 30: 100% of revenue | iQ Group Global, iQX, OncoTEX, Biosensx, New Frontier |
| Listed and unlisted biotech/medtech | Stated target market | No disclosed third-party clients in FY2020 |
| Governments, institutions, individuals | Stated in boilerplate | No disclosed revenue |
| US life science companies | US subsidiaries (iQ Capital (USA) LLC etc.) | Revenue geographically disclosed as Australia only |
End-markets: biotechnology, medical devices and diagnostics (notably saliva-based biosensors developed within the wider iQ Group), oncology (OncoTEX associate) and pharmaceutical services.
Strategy
Stated strategy (FY2019–FY2020 Annual Reports)
The main strategic themes in the last two annual reports were:
-
Distribution build-out across Australia and the USA, raising the group's profile in the life science industry and positioning it in capital markets (FY2019 and FY2020 Chair's Reports).
-
US expansion through new projects and collaborations with US business partners and investment banking via iQ Capital (USA) LLC. Management said several significant contracts had been signed, giving a pipeline for the next 12–24 months (FY2020).
-
IP commercialisation advisory, including acquiring and licensing life science assets for new and existing clients, which management expected to generate more corporate advisory work (FY2020).
-
Mission statement (FY2020 Chair): to make a difference in the Australian life science sector by giving it access to capital markets and the opportunity to become a major global force.
Initiatives register (last 24 months of disclosure, FY2019–FY2021)
| Date | Initiative | Detail | Outcome |
|---|---|---|---|
| FY2020 | Cost-saving programme | Operational review produced positive Q4 FY2020 operating cash flow of A$203k. "Full impact" expected in FY2021 | Full-year FY2020 operating cash flow still −A$862k |
| 31 Dec 2019 | Related-party bond | A$927k from iQX at 9% | Drawn; maturity 30 Jun 2022 fell after administration |
| 30 Apr 2020 | "Strategic partnership" / liquidity facility | A$3m iQX working capital facility at 9%, maturing 30 Jun 2022 | Undrawn at 30 Jun 2020; iQX entered administration in Mar 2022 |
| FY2020 | US business partnerships | Unnamed US partners; "several significant contracts" | No US revenue recognised in FY2020 |
| FY2019–FY2020 | Associate investments | Further investment in New Frontier Holdings LLC (A$74,942 in FY2020; A$82,800 in FY2019) | Equity-accounted; OncoTEX valuation later treated as confidential in court ([2022] FCA 397) |
| FY2020 | Board restructuring | Executive Chair model adopted | Independence removed |
ESG and sustainability commitments
None disclosed. The Directors' Report stated that operations were not subject to significant environmental regulation.
Medium-term targets and guidance
Not publicly disclosed. The company never published quantitative revenue, margin or return targets.
Products & Services
iQ3Corp did not publish a priced service catalogue. The services below are drawn from the FY2019 and FY2020 annual reports and aggregator profiles derived from company disclosures. Pricing was disclosed only at policy level: fixed price or hourly rate, recognised over time.
Consulting Services segment
| Service | Description | Target customer | Pricing model | Evidence |
|---|---|---|---|---|
| Capital raising | Arranging equity capital for listed and unlisted life science companies | Early-stage and listed biotech/medtech | Fees (fixed/hourly; success fees not separately disclosed) | FY2020 AR principal activities |
| IPO and listing advisory | Preparing companies for ASX/NSX listing | Pre-IPO life science companies | — | MarketBeat/Investing.com profiles |
| NSX nominated adviser services | Acting as nominated adviser for NSX-listed issuers | NSX issuers (including related parties) | — | Aggregator profiles |
| Mergers and acquisitions | Sell-side and buy-side advisory | Life science corporates | — | FY2020 AR; aggregator profiles |
| Private equity advisory | Private capital transactions | Life science companies | — | Aggregator profiles |
| Structured finance / structured investment products | Structured funding solutions | — | — | Aggregator profiles; Lei Xu former title |
| Restructuring and capital structure | Balance sheet and capital structure advice | Distressed/transitional companies | — | FY2020 AR |
| Strategic and commercialisation advisory | Business model, market entry, licensing and partnering strategy for new life science IP | Boards and executives of IP-owning companies | — | FY2020 AR Review of operations |
| Asset corporatisation | "Finding, funding, corporatising and capitalising early stage biotech assets" | Early-stage biotech assets | — | FY2020 AR (Lei Xu biography) |
| US investment banking (via iQ Capital (USA) LLC) | US capital-markets activity | US life science companies | — | FY2020 AR going-concern note |
Shared Services segment
| Service | Description | Customer | FY2020 revenue (AUD) |
|---|---|---|---|
| Office sharing and shared services | Office space and administrative services recharged to related entities | iQ Group companies | 139,757 |
Note that iQ3Corp was also a net buyer of shared services. It paid A$1,614,105 in office-sharing costs to related parties in FY2020 (FY2019: A$1,028,541), more than ten times what it earned from shared services.
Equity interests that functioned as "portfolio products"
| Holding | Nature | Carrying value 30 Jun 2020 (AUD) |
|---|---|---|
| New Frontier Holdings LLC (40%) and OncoTEX Holdings Inc (40.5%) | Equity-accounted associates | 581,206 (combined line) |
| Shares in a listed company (unnamed) | FVOCI financial asset, Level 1 | 70,126 |
| Licences | Indefinite-life intangible | 307,986 |
Financial Narrative
Coverage: FY2016–FY2020 audited (FY2020 Annual Report 5-year table plus full FY2019/FY2020 statements).
Income statement (chartable)
Derivations: EBIT = loss before tax + finance costs − interest revenue. FY2020: −2,212,596 + 157,853 − 61 = −2,054,804. FY2019: −1,098,530 + 64,842 − 12 = −1,033,700. EBITDA adds depreciation (FY2020 A$25,568; FY2019 A$35,317). There was no amortisation. Income tax expense was nil in both years. Sources: FY2020 AR statement of profit or loss, Note 7 and the remuneration report's 5-year table. FY2018 EPS is reported as nil.
Margins (chartable)
Revenue CAGR: FY2016–FY2020 (4 years) 34.4%; FY2017–FY2020 (3 years) 5.5%; FY2018–FY2020 (2 years) 3.3%.
Commentary. The revenue series has two phases. FY2016–FY2017 shows a steep ramp from a small base (+177.5%) as the newly listed company built up related-party mandates. FY2017–FY2020 shows a plateau between A$5.9m and A$6.9m. The best year for profitability was FY2018, which was near breakeven. Profitability then deteriorated even as revenue rose in FY2020. Gross profit fell 31% to A$2.95m while revenue rose 12%, because cost of sales more than doubled from A$1.87m to A$3.95m. Management attributed this to higher employee-related costs within cost of sales, incurred to build the infrastructure needed for its strategy. Office-sharing costs paid to related parties rose 57% to A$1.61m, and consultancy fees nearly quadrupled from A$0.25m to A$0.94m.
Revenue therefore grew without operating leverage. Because both revenue (fees from related parties) and a large share of costs (office-sharing charges paid to related parties) were set within the group, reported margins say more about intragroup pricing than about any market-tested advisory economics. The FY2020 figure also includes A$191k of COVID-19 government support in other income. Without it, the loss would have been about A$2.40m.
Operating expense detail (FY2019–FY2020)
Source: FY2020 AR statement of profit or loss and Note 7.
Balance sheet (chartable)
FY2018 figures are opening balances from the FY2020 statements of cash flows and changes in equity. Total debt at 30 June 2020 is the iQX related-party bond (A$927,000 principal plus A$42,559 accrued interest), classified as non-current with maturity on 30 June 2022. Source: FY2020 AR statement of financial position and Notes 9, 10, 18 and 20.
Commentary. The balance sheet shows rapid capital erosion. Equity fell from A$1.90m (30 June 2018) to A$0.89m (30 June 2019) and then to a deficiency of A$0.99m (30 June 2020), with no new equity raised after the IPO (contributed equity unchanged at A$7.18m). Related-party receivables made up 68% of total assets, so the asset base largely consisted of claims on sister companies that later went into administration themselves. In the administration, those receivables would have been recoverable only as unsecured claims against insolvent estates. The administrators said that, in a liquidation, unsecured creditors of the group entities were unlikely to receive any distribution. Net current liabilities widened from A$0.13m to A$0.96m. Sundry payables and accrued expenses rose from A$0.99m to A$2.35m, which suggests the company was stretching payments to creditors.
Cash flow (chartable)
Source: FY2020 AR statement of cash flows. Management reported positive operating cash flow of A$203k in Q4 FY2020 after cost-saving initiatives, a quarterly figure not separately audited. The full-year A$862k operating outflow was funded almost exactly by the A$927k related-party bond.
Ratios (chartable)
Notes: FY2020 ROE and debt to equity are not meaningful because equity was negative. ROIC is not meaningful (negative NOPAT, negative equity). Net debt to EBITDA is not meaningful because EBITDA was negative. Interest coverage uses interest expense (FY2020 A$144,132; FY2019 A$55,016). A full cash conversion cycle is not meaningful for a services firm with no inventory, so DSO is shown instead.
Synthesis of trends. The data shows (1) revenue stalling at about A$6–7m after FY2017; (2) a structural rise in costs from FY2019, partly charged by related parties; (3) negative and worsening cash generation; (4) equity eliminated within two years; and (5) a growing reliance on related-party debt. The going-concern material uncertainty in FY2020 was the formal warning of the March 2022 collapse.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products/services | Customers |
|---|---|---|---|
Consulting services | Capital raising and corporate advisory fees | IPO/listing advisory, capital raising, M&A, structured finance, restructuring, strategic advisory, commercialisation advisory | Related parties only (FY2020) |
Shared services | Office and shared services revenue | Office space, administration and shared services recharged to group companies | Related parties only |
Revenue by Segment
| Segment | FY2019 | FY2020 |
|---|---|---|
Consulting services revenue (AUD K) | 5,648 | 6,760 |
Shared services revenue (AUD K) | 513 | 140 |
Total revenue (AUD K) | 6,161 | 6,900 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%) and Segment Margins & Growth (%)
| Segment metric | FY2019 | FY2020 |
|---|---|---|
Consulting services share of revenue (%) | 91.7 | 98.0 |
Shared services share of revenue (%) | 8.3 | 2.0 |
Consulting services YoY growth (%) | — | 19.7 |
Shared services YoY growth (%) | — | -72.8 |
Group Entities
| Entity | Jurisdiction | Ownership | Role (inferred where not stated) |
|---|---|---|---|
iQ3Corp Limited | Australia | Parent | Listed holding and advisory company |
iQ Group (Global) LLC | USA | 100% | US holding/operations |
The Biotech Company Pty Ltd | Australia | 100% | — |
Sonholdings LLC (trading as Son Enterprise in NY) | USA | 100% | New York operations |
iQ Capital (USA) LLC | USA | 100% | US investment banking (cited in going-concern note as a source of future funds) |
The iQ Capital (Operations) LLC | USA | 100% | US operations |
Capital Labs Pty Ltd | Australia | 100% | — |
New Frontier Holdings LLC | USA | 40% associate | Holds Nereid Enterprises Pty Ltd (Aus) and Nereid Enterprises LLC (USA) |
OncoTEX Holdings Inc | USA | 40.5% associate | Holds OncoTEX Inc (USA) and OncoTEX Pty Ltd (Aus); oncology venture |
“—” = not publicly disclosed.
Group Entities — The iQ Group Global Ltd
| Entity | Listing | Function (per administrators' evidence) |
|---|---|---|
The iQ Group Global Ltd (formerly iQnovate) | NSX, 15 Dec 2011 – delisted 19 Sep 2022 | Asset manager of scientific IP; finds, funds and develops bioscience discoveries |
iQX Limited | NSX, 10 Dec 2013 – delisted 19 Sep 2022 | Bioscience investment funds manager; iQ3Corp's lender |
Farmaforce Limited | ASX, 27 Oct 2015 – delisted 26 Aug 2022 (as A.C.N. 167 748 843 Limited) | Contract pharmaceutical sales force; principal operating company |
iQ3Corp Ltd | ASX, 18 May 2015 – delisted 26 Aug 2022 | Life science corporate finance advisory |
Income Statement and Margin Analysis (%)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue (AUD K) | 2,118 | 5,875 | 6,462 | 6,161 | 6,900 |
Revenue YoY growth (%) | — | 177.5 | 10.0 | -4.7 | 12.0 |
Gross profit (AUD K, FY2019 restated) | — | — | — | 4,293 | 2,946 |
EBIT / operating result (AUD K, derived) | — | — | — | -1,034 | -2,055 |
EBITDA (AUD K, derived) | — | — | — | -998 | -2,029 |
Pre-tax income (AUD K) | — | — | — | -1,099 | -2,213 |
Net income (AUD K) | -1,988 | -50 | -1 | -1,099 | -2,213 |
EPS basic (AUD cents) | -1.95 | -0.05 | 0 | -1.06 | -2.13 |
EPS diluted (AUD cents) | -1.95 | -0.05 | 0 | -1.06 | -2.13 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin
| Margin | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Gross margin (%) | — | — | — | 69.7 | 42.7 |
EBIT margin (%) | — | — | — | -16.8 | -29.8 |
EBITDA margin (%) | — | — | — | -16.2 | -29.4 |
Net margin (%) | -93.9 | -0.8 | 0.0 | -17.8 | -32.1 |
Expense line
| Expense line | FY2019 | FY2020 |
|---|---|---|
Cost of sales (AUD K, FY2019 restated) | 1,867 | 3,954 |
Employee benefits expense (AUD K, restated) | 2,871 | 1,759 |
Office sharing cost (AUD K) | 1,029 | 1,614 |
Consultancy fees (AUD K) | 251 | 942 |
Other expenses (AUD K, restated) | 1,043 | 898 |
Finance costs (AUD K) | 65 | 158 |
Depreciation (AUD K) | 35 | 26 |
Share-based payments (AUD K, within employee costs) | 243 | 58 |
Bonuses (AUD K, within employee costs) | 487 | 0 |
Balance Sheet
| Metric | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Total assets (AUD K) | — | 3,695 | 3,635 |
Cash and equivalents (AUD K) | 513 | 253 | 227 |
Trade and other receivables (AUD K) | — | 2,115 | 2,373 |
of which related-party receivables gross (AUD K) | — | 2,224 | 2,477 |
Total current assets (AUD K) | — | 2,675 | 2,606 |
Total current liabilities (AUD K) | — | 2,803 | 3,566 |
Short-term debt (AUD K) | — | 0 | 0 |
Long-term debt (AUD K) | — | 0 | 970 |
Total debt (AUD K) | — | 0 | 970 |
Net debt (AUD K; negative = net cash) | — | -253 | 742 |
Goodwill and intangibles (AUD K) | — | 301 | 308 |
Investments in associates (AUD K) | — | 441 | 581 |
Working capital (AUD K) | — | -129 | -960 |
Total equity (AUD K) | 1,900 | 892 | -988 |
Accumulated losses (AUD K) | -4,930 | -6,028 | -8,241 |
Contributed equity (AUD K) | 7,184 | 7,184 | 7,184 |
Cash Flow
| Metric | FY2019 | FY2020 |
|---|---|---|
Receipts from customers (AUD K) | 6,289 | 7,211 |
Payments to suppliers and employees (AUD K) | -6,404 | -8,154 |
Operating cash flow (AUD K) | -176 | -862 |
Capex: PP&E payments (AUD K) | 0 | -18 |
Free cash flow (AUD K) | -176 | -880 |
Investment in associates (AUD K) | -83 | -75 |
Proceeds from borrowings (AUD K) | 0 | 927 |
Dividends paid (AUD K) | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 |
Net change in cash (AUD K) | -259 | -28 |
Financial Analysis
| Item | Value | Source | Verification status |
|---|---|---|---|
Results release date | 27 Aug 2021 | Investing.com | — |
Revenue | 329.04K (currency/period unclear) | Investing.com | It would imply a 95% revenue collapse from FY2020 |
EPS | −0.03 (AUD) | Investing.com | Would imply a loss of about A$3m on about 104m shares |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2019 | FY2020 |
|---|---|---|
ROE (%; average equity) | -78.7 | — |
ROA (%; average total assets where available) | -29.7 | -60.4 |
Current ratio (x) | 0.95 | 0.73 |
Debt to equity (x) | 0.00 | — |
Interest coverage, EBIT / interest expense (x) | -18.8 | -14.3 |
Asset turnover (x) | 1.67 | 1.88 |
Days sales outstanding (days) | 125 | 126 |
Revenue by Region
| Region | FY2019 | FY2020 |
|---|---|---|
Australia revenue (AUD K) | 6,161 | 6,900 |
United States revenue (AUD K) | 0 | 0 |
Rest of world revenue (AUD K) | 0 | 0 |
Revenue by Region by Segment × Region
| Segment × region | FY2019 | FY2020 |
|---|---|---|
Consulting services, Australia (AUD K) | 5,648 | 6,760 |
Shared services, Australia (AUD K) | 513 | 140 |
Share Price and Market Valuation
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.25 | 0.25 | 0.25 | 0.29 | 0.13 |
Implied market cap at 30 June (AUD Mn, 103.925m shares) | 26.0 | 26.0 | 26.0 | 30.1 | 13.5 |
Performance Measure Details
| Performance measure | Value |
|---|---|
IPO price (May 2015) | A$0.30 |
Last quoted price | A$0.12 (prior close A$0.125); thinly traded (3-month average volume about 5.8k shares) — Investing.com historical page |
Return IPO → FY2020 close | −56.7% |
Return IPO → last quote | −60.0% |
1-year / 3-year / 5-year return to Oct 2026 | Not applicable (delisted Aug 2022). Realisable equity value likely nil given the administrators' creditor outlook |
Relative performance (Market Index, vs ASX 200, 1 year, historical) | −23.58% |
Valuation Multiples
| Multiple | iQ3Corp (FY2020 basis, at A$0.13) | Comment |
|---|---|---|
P/E | Not meaningful (loss) | — |
EV/EBITDA | Not meaningful (negative EBITDA) | EV ≈ A$13.5m + A$0.74m net debt ≈ A$14.3m |
EV/Sales | 2.1x | Historical only |
P/B | Not meaningful (negative book value) | — |
Capital Markets
| Item | Status |
|---|---|
Analyst coverage / consensus | None. MarketBeat shows no price target or consensus rating |
Dividend history | None paid, declared or recommended in FY2016–FY2020 |
Buyback authorisations | None ("There is no current on-market share buy-back", FY2020 AR Note 20) |
Capital raisings after IPO | None (contributed equity unchanged at A$7,184,247 in FY2018–FY2020) |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile (30 Jun 2020) | A$42,559 accrued interest within 1 year; A$927,000 bond principal due 30 Jun 2022 (1–2 years); nothing beyond |
Unrecognised tax losses | Deferred tax assets not recognised: A$4,003,325 (FY2020) vs A$2,140,438 (FY2019) |
Performance rights outstanding | 1,815,000 under the Employee Benefits Plan (at report date, Aug 2020) |
Analyst Conclusions
Management guidance
The last management outlook (FY2020 Annual Report, August 2020) expected US contracts to produce a pipeline over 12–24 months and the full benefit of cost savings in FY2021. No quantitative guidance was ever issued. No management guidance applies today, because control rests with the external administrators.
Consensus
None exists. No analyst coverage was identified at any point.
Bull case (historical, with what has since happened)
-
Captive pipeline: related-party mandates delivered A$6.8m of advisory fees in FY2020 (+19.7%). If group companies had kept raising capital, iQ3Corp would have kept earning fees. What happened: the group failed in March 2022.
-
Cost flexibility: a Q4 FY2020 operating cash surplus of A$203k showed a path to cash breakeven. insolvency followed.
-
Hidden associate value: the 40.5% OncoTEX stake was material enough for a confidential court valuation, giving potential recovery value. What happened: the result of any realisation is not publicly disclosed.
Bear case (all substantiated)
-
Circular economics: 100% related-party revenue, A$1.6m of related-party office charges and related-party debt meant reported profitability was a matter of intragroup pricing.
-
Balance sheet failure: negative equity (−A$0.99m), net current liabilities (−A$0.96m) and receivables owed by entities that later became insolvent.
-
Governance: an insider-only board from March 2020, administrators' findings on intercompany loans and spending, and an ASIC referral.
Catalysts and monitorables for the next 12 months
| Monitorable | Why it matters | Where to check |
|---|---|---|
| Final outcome of the administration (DOCA vs liquidation) and any dividend to creditors | Determines whether any residual value exists for stakeholders | ASIC published notices; administrators' creditor portal |
| ASIC action on directors following the administrators' report | Potential disqualification or civil penalty proceedings | ASIC media releases; Federal Court listings |
| Disrupt Group litigation outcome | About A$214m claim against group entities | Court records |
| Realisation of OncoTEX and New Frontier interests | Possible creditor recoveries | Liquidator/administrator reports |
| Deregistration of iQ3Corp Ltd (ACN 160 238 282) | Final legal end of the entity | ASIC Connect company register |
Analyst verdict
iQ3Corp Ltd is no longer an investable security. It was removed from the ASX Official List on 26 August 2022 and has been in external administration since March 2022, and its administrators told creditors that unsecured creditors of the group entities were unlikely to receive anything in a liquidation. On that evidence, holders of its 103.9 million ordinary shares should assume their equity is worthless unless the administration outcome shows otherwise.
On paper, iQ3Corp met the profile of a promising niche advisory boutique. It had an oversubscribed IPO, revenue that more than tripled in four years, a credentialed founder and a clear sector specialisation. The filings, however, contained every warning an analyst needed well before the collapse. Every dollar of FY2020 revenue came from related parties, and related-party receivables made up two-thirds of total assets. Office costs and debt funding came from the same group of companies. The company never raised equity after its IPO, yet accumulated losses rose from A$4.9m to A$8.2m in two years. The auditor flagged going concern, related party transactions and intangibles as key audit matters. In March 2020 the board removed its last independent directors and installed the Group CEO as Executive Chair, chairing both the audit and remuneration committees, while raising his fixed pay by 25% in a record-loss year.
The administrators' later findings were the natural consequence of these disclosures. They found mutually dependent group entities, unexplained intercompany write-offs, cross-entity payroll and questioned spending.
For risk professionals, the takeaway is that a single disclosure line ("revenue is derived only from related parties") combined with a negative-equity balance sheet should override any growth narrative. Investors should not view iQ3Corp as a turnaround candidate. The key open items are now forensic: the administration's final outcome, any ASIC action, and the Disrupt litigation.
APPENDIX — SOURCES
1: iQ3Corp Limited, 2020 Annual Report (year ended 30 Jun 2020), lodged 23 Oct 2020 — https://www.aspecthuntley.com.au/asxdata/20201023/pdf/02298344.pdf — Financials FY2016–FY2020, segments, governance, remuneration, entities
2: iQ3Corp Ltd, Appendix 4E and 2019 Annual Report (30 Aug 2019) — https://announcements.asx.com.au/asxpdf/20190830/pdf/4482njwl9nqmlw.pdf — FY2019 results; positioning
3: Robinson, in the matter of Farmaforce Limited (Administrators Appointed) [2022] FCA 397 (6 Apr 2022) — https://au.vlex.com/vid/robinson-in-the-matter-926800848 — Administration, listing dates, group structure findings
4: ASX Market Announcement, Removal from Official List – Annual Listing Fees (29 Aug 2022) — https://announcements.asx.com.au/asxpdf/20220829/pdf/45df4lf4w3tdxr.pdf — Delisting
5: ASX Market Announcement, Suspension from Official Quotation (22 Aug 2022) — https://announcements.asx.com.au/asxpdf/20220822/pdf/45d3db31lnq39s.pdf — Suspension status
6: FNN, "IQ3Corp Prospectus Offer Closes Oversubscribed" (11 May 2015) — https://www.finnewsnetwork.com.au/companyreports/iq3corp/20150511/iq3corp-prospectus-offer-closes-oversubscribed — IPO terms
7: Market Index, IQ3 profile — https://www.marketindex.com.au/asx/iq3 — Shareholders, auditor, relative performance
8: Investing.com, iQ3Corp Ltd historical data — https://uk.investing.com/equities/iq3corp-ltd — Last price; FY2021 aggregator data
9: MarketBeat, ASX:IQ3 profile — https://www.marketbeat.com/stocks/ASX/IQ3 — Service lines, incorporation year
10: MarketScreener insider profiles (Kosmas Dimitriou; George Syrmalis) — Officer changes; biography
11: CB Insights, iQ Group Global page (summarising July 2022 media coverage of the administrators' report) — https://www.cbinsights.com/company/iq-group-global — Creditor claims, ASIC referral, Disrupt claim, spending findings
12: NSX announcement registers for IQG and IQX — https://www.nsx.com.au/marketdata/company-directory/announcements/IQG/ — Group administration and delisting dates
13: Wikipedia, "IQnovate" — https://en.wikipedia.org/wiki/IQnovate — Group background; AFR citation (11 Mar 2022)
14: IQX Limited FY2013 financial statements (NSX) — https://www.nsx.com.au/ftp/news/021728022.PDF — iQX establishment; early group history
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Prior roles | Education | Holdings (30 Jun 2020) |
|---|---|---|---|---|---|
Dr George Syrmalis | Executive Chair, Executive Director and Group CEO | Group CEO throughout FY2020; Chair/Director from 20 Mar 2020 | Founder, CEO and Chair, Bionuclear Group SA (1995–2005). Chair/ED of The iQ Group Global and iQX; ED of Farmaforce. Per MarketScreener: formerly Chairman of Intelligent Bio Solutions Inc., Medical Director at UCB Biopharma, Head of Medical Affairs at Sanofi-Aventis France | M.D., PhD; trained in nuclear medicine–radiation immunology | 20,495,112 shares (~19.7%); 765,000 performance rights |
Monika Pawel | Non-Executive Director | From 27 Aug 2019 | Chief of Staff, The iQ Group Global. Previously R&D, sales and medical marketing at Roche and IQVIA; managed teams in Japan, Germany and the UK at CSL | BSc (Hons) Monash; MSc Medical Science UNSW; MBA Melbourne; MSc Major Programme Management, Oxford | Nil |
Lei Xu | Executive Director | ED from 20 Mar 2020; joined iQ3Corp in 2014 | Director APAC; Director, Structured Investment Products (iQ3Corp) | BSc Accounting, Jiangsu; MSc Management, Stirling; Executive MBA, AGSM; FCCA; China Certified Tax Agent | 20,000 shares; 260,000 performance rights |
Gerardo Incollingo | Company Secretary (FY2020) | — | Managing Director, LCI Partners; company secretary of Farmaforce, iQX and iQ Group Global | BCom (Wollongong); CPA | — |
Kosmas Dimitriou | Company Secretary (from Jan 2022, per MarketScreener) | 2,022 | Former NED (2013–20 Mar 2020); Chairman of iQX; tax lawyer | BCom/LLB (Western Sydney); Dip Legal Practice (Tax), Sydney | — |
“—” = not publicly disclosed.
Board of Directors — Peter Coolentianos
| Name | Role | Departure | Background |
|---|---|---|---|
Peter Coolentianos | Independent NED and Chair; chaired Audit & Risk and Remuneration & Nomination Committees | Resigned 20 Mar 2020 | 35 years in accounting; 22 years as partner at Economos Chartered Accountants; CPA |
Kosmas Dimitriou | Independent NED | Resigned 20 Mar 2020 | Tax lawyer, 18+ years; adviser to government and ATO on tax policy |
Jimena Hurtado | NED | Resigned 27 Aug 2019 | 19+ years in pharma/medtech; former GM of Clinical Research Corporation |
Directors' Remuneration
| Name | Cash salary/fees | Bonus | Other | Super | Long service leave | Equity | Total |
|---|---|---|---|---|---|---|---|
Dr George Syrmalis | 499,234 | 0 | 71,573 | 47,427 | 48,776 | 18,360 | 685,370 |
Lei Xu (from 20 Mar 2020) | 70,611 | 0 | 17,199 | 6,708 | 22,478 | 6,000 | 122,996 |
Monika Pawel (from 27 Aug 2019) | 31,004 | 0 | 0 | 2,945 | 0 | 0 | 33,949 |
Peter Coolentianos (to 20 Mar 2020) | 30,822 | 0 | 0 | 2,928 | 0 | 0 | 33,750 |
Kosmas Dimitriou (to 20 Mar 2020) | 27,398 | 0 | 0 | 2,603 | 0 | 0 | 30,001 |
Jimena Hurtado (to 27 Aug 2019) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total KMP | 659,069 | 0 | 88,772 | 62,611 | 71,254 | 24,360 | 906,066 |
KMP remuneration | FY2019 | FY2020 | — | — | — | — | — |
Total KMP remuneration (AUD K) | 804 | 906 | — | — | — | — | — |
CEO total remuneration (AUD K) | 679 | 685 | — | — | — | — | — |
CEO pay as % of group revenue (%) | 11.0 | 9.9 | — | — | — | — | — |
KMP pay as % of group revenue (%) | 13.1 | 13.1 | — | — | — | — | — |
Directors' Remuneration (Annual)
| Governance attribute | Status after 20 Mar 2020 | Assessment |
|---|---|---|
Board size | 3 | Minimal |
Independent directors | 0 of 3. Pawel was a non-executive but was Chief of Staff at related party iQ Group Global; Syrmalis and Xu were executives | Departure from ASX Corporate Governance Principles Recommendation 2.4 (majority independent) |
Chair/CEO separation | No. Syrmalis was both Executive Chair and Group CEO | Departure from Recommendation 2.5 |
Audit & Risk Committee | Chaired by Syrmalis; members Pawel and Xu | Executive-chaired audit committee; no independent members |
Remuneration & Nomination Committee | Chaired by Syrmalis; members Pawel and Xu | CEO chairing the committee that sets his own pay |
Board meetings FY2020 | Pawel 6/6; Dimitriou and Coolentianos 5/5; Syrmalis and Xu 1/1 (post-appointment) | — |
Remuneration consultants | None engaged in FY2020 | — |
Corporate governance statement | Claims "substantial" compliance with ASX Principles (3rd ed.) "to the extent appropriate" | Board structure suggests material exceptions |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | Bioworx Capital Pty Ltd | 17,905,000 | 17.16 |
| 2 | Derivative Investments Pty Ltd | 14,061,112 | 13.48 |
| 3 | Biodynamic Investments Pty Ltd | 8,888,888 | 8.52 |
| 4 | Zeolite Holdings Pty Ltd (Zeolite Discretionary A/C) | 8,800,000 | 8.43 |
| 5 | Babi Holdings Pty Ltd (CLT Super Fund) | 4,000,000 | 3.83 |
| 6 | Champ Power Holdings Ltd | 3,500,000 | 3.35 |
| 7 | BG Ventures Ltd | 3,250,000 | 3.11 |
| 8 | Biofarma Investments Pty Ltd (Biofarma A/C) | 1,750,000 | 1.68 |
| 9 | Odams Pty Ltd (The Rangoon A/C) | 1,716,666 | 1.65 |
| 10 | Oceana Horizon Pty Ltd (Oceana Horizon Invest Super) | 1,000,000 | 0.96 |
Competitive Landscape
Key Competitors
| # | Competitor | Type | Relevance | Comparative revenue |
|---|---|---|---|---|
| 1 | Bell Potter Securities (Bell Financial Group, ASX: BFG) | Full-service broker | Leading small/mid-cap healthcare ECM in Australia | — |
| 2 | Canaccord Genuity (Australia) | Global mid-market investment bank | Active life science ECM | — |
| 3 | Morgans Financial | Broker/adviser | Healthcare IPOs and placements | — |
| 4 | Wilsons Advisory | Broker/advisory | Healthcare research and ECM | — |
| 5 | Taylor Collison | Boutique broker | Small-cap biotech placements | Private |
| 6 | Evolution Capital | Boutique | Small-cap biotech/healthcare raisings | Private |
| 7 | Henslow | Corporate advisory boutique | Life science M&A and capital | Private |
| 8 | Ord Minnett | Broker | Healthcare ECM | Private |
| 9 | Euroz Hartleys (Euroz Hartleys Group) | Broker | Small-cap ECM | — |
| 10 | MST Financial | Research/ECM boutique | Small-cap ECM | — |
| 11 | Petra Capital | Boutique | Small-cap ECM | Private |
| 12 | US small-cap banks (e.g., Maxim Group, ThinkEquity) | US investment banks | US microcap healthcare IPOs | — |
Peer Comparison FY2020
| Metric | iQ3Corp FY2020 | Peer data |
|---|---|---|
Revenue (AUD Mn) | 6.9 | — |
Revenue growth (%) | 12.0 | — |
EBITDA margin (%) | -29.4 | — |
R&D intensity (%) | 0 | Not applicable to brokers |
Share of revenue from related parties (%) | 100 | Typically minimal for peers (qualitative) |
Recent Developments
Note on window: * There have been no company-originated disclosures since early 2022. That is well outside the 18 months before October 2026, which saw no reported developments.



